Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission.

@article{Vose2006MantleCL,
  title={Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission.},
  author={Julie Marie Vose and Fausto R. Loberiza and Philip Jay Bierman and Greg R Bociek and JamesO. Armitage},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={7511}
}
7511 Background: Although patients (pts) with MCL have a high response rate to standard chemotherapy, they continue to relapse with no plateau in long term disease-free survival. The use of dose intense induction therapy such as HyperCVAD (M-C) ±Rituximab(R) and high-dose therapy and stem cell may improve these results. In this analysis the outcomes of pts receiving a standard anthracycline induction therapy or HyperCVAD(M-C)(±R) then followed by a stem cell transplant in first complete (CR1… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.

  • American journal of hematology
  • 2013
VIEW 14 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.

  • American journal of hematology
  • 2012
VIEW 3 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

Similar Papers

Loading similar papers…